
Salia Farrokh describes how neurocritical care pharmacists have moved from answering questions to leading research, policy, and teaching, and why health systems must fund dedicated ICU pharmacists and protected time to sustain that growth.
Ofatumumab (Kesimpta) is a CD20-directed cytolytic antibody indicated for the treatment of relapsing forms of multiple sclerosis.
Medication Pearl of the Day: Ofatumumab (Kesimpta)
Indication: Ofatumumab(Kesimpta) is a CD20-directed cytolytic antibody indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
Insight:
Source:




